These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30241550)

  • 1. High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study.
    Björklund J; Laursen TL; Sandahl TD; Møller HJ; Vilstrup H; Ott P; Grønbæk H
    Orphanet J Rare Dis; 2018 Sep; 13(1):169. PubMed ID: 30241550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease.
    Glavind E; Gotthardt DN; Pfeiffenberger J; Sandahl TD; Bashlekova T; Willemoe GL; Hasselby JP; Weiss KH; Møller HJ; Vilstrup H; Lee WM; Schilsky ML; Ott P; Grønbæk H
    Orphanet J Rare Dis; 2020 Jul; 15(1):173. PubMed ID: 32615997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
    Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
    J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
    Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
    J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C.
    Kazankov K; Barrera F; Møller HJ; Bibby BM; Vilstrup H; George J; Grønbaek H
    Hepatology; 2014 Aug; 60(2):521-30. PubMed ID: 24623375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
    Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
    Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lifestyle intervention on soluble CD163, a macrophage activation marker, in patients with non-alcoholic fatty liver disease.
    Rødgaard-Hansen S; St George A; Kazankov K; Bauman A; George J; Grønbæk H; Jon Møller H
    Scand J Clin Lab Invest; 2017 Nov; 77(7):498-504. PubMed ID: 28715286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
    Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
    J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The macrophage activation marker sCD163 is associated with changes in NAFLD and metabolic profile during lifestyle intervention in obese children.
    Kazankov K; Møller HJ; Lange A; Birkebaek NH; Holland-Fischer P; Solvig J; Hørlyck A; Kristensen K; Rittig S; Handberg A; Vilstrup H; Grønbaek H
    Pediatr Obes; 2015 Jun; 10(3):226-33. PubMed ID: 25073966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
    Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
    J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.
    Bossen L; Vesterhus M; Hov JR; Färkkilä M; Rosenberg WM; Møller HJ; Boberg KM; Karlsen TH; Grønbæk H
    Clin Transl Gastroenterol; 2021 Mar; 12(3):e00315. PubMed ID: 33646203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease.
    Kazankov K; Alisi A; Møller HJ; De Vito R; Rittig S; Mahler B; Nobili V; Grønbæk H
    J Pediatr Gastroenterol Nutr; 2018 Nov; 67(5):635-642. PubMed ID: 30074574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study.
    Andersen ES; Rødgaard-Hansen S; Moessner B; Christensen PB; Møller HJ; Weis N
    Eur J Clin Microbiol Infect Dis; 2014 Jan; 33(1):117-22. PubMed ID: 24424890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinoma.
    Kazankov K; Rode A; Simonsen K; Villadsen GE; Nicoll A; Møller HJ; Lim L; Angus P; Kronborg I; Arachchi N; Gorelik A; Liew D; Vilstrup H; Frystyk J; Grønbæk H
    Scand J Clin Lab Invest; 2016; 76(1):64-73. PubMed ID: 26549495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology.
    Lund Laursen T; Brøckner Siggard C; Kazankov K; Damgaard Sandahl T; Møller HJ; Ong A; Douglas MW; George J; Tarp B; Hagelskjaer Kristensen L; Lund Laursen A; Hiramatsu A; Nakahara T; Chayama K; Grønbaek H
    Scand J Gastroenterol; 2018 Aug; 53(8):986-993. PubMed ID: 29987961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis.
    Bossen L; Rebora P; Bernuzzi F; Jepsen P; Gerussi A; Andreone P; Galli A; Terziroli B; Alvaro D; Labbadia G; Aloise C; Baiocchi L; Giannini E; Abenavoli L; Toniutto P; Marra F; Marzioni M; Niro G; Floreani A; Møller HJ; Valsecchi MG; Carbone M; Grønbaek H; Invernizzi P
    Liver Int; 2020 Jun; 40(6):1408-1414. PubMed ID: 32279422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
    Grønbæk H; Rødgaard-Hansen S; Aagaard NK; Arroyo V; Moestrup SK; Garcia E; Solà E; Domenicali M; Piano S; Vilstrup H; Møller HJ;
    J Hepatol; 2016 Apr; 64(4):813-22. PubMed ID: 26639396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
    Greisen SR; Møller HJ; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Junker P; Østergaard M; Hvid M; Deleuran B
    Clin Exp Rheumatol; 2015; 33(4):498-502. PubMed ID: 25962601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.